Fig. 1

miR-4732-3p is highly expressed in serum fucosylated exosomes but downregulated in NSCLC tissues. A Venn diagram exhibiting the overlap of DEmiRs in serum fucosylated exosomes from early LUAD patients compared with both BPNs and HCs groups, together with DEmiRs in NSCLC tissues. B qRT-PCR was performed to determine miR-4732-3p levels in serum fucosylated exosomes from NSCLC patients (n = 96), BPNs (n = 30), and HCs (n = 32). C ROC curve analysis of serum fucosylated exosomal miR-4732-3p for diagnosing NSCLC patients form BPNs and HCs. D Levels of miR-4732-3p were detected via qRT-PCR in serum fucosylated exosomes from NSCLC patients at diverse stages: Tis (n = 31), Stage I/II (n = 34), and Stage III/IV (n = 31). E The ability of serum fucosylated exosomal miR-4732-3p to discriminate NSCLC patients at diverse stages was evaluated using ROC curve analysis. F-G Expression of miR-4732-3p in cancerous tissues according to the GEDs (F) and ENCORI (G) databases. H-I miR-4732-3p levels in NSCLC tissues were evaluated by the fluorescence intensity via FISH (H) and relative expression via qRT-PCR (I) analysis. J Kaplan–Meier survival analysis of NSCLC patients according to hsa-miR-4732 expression. Data are shown as the mean ± SD from at least three independent experiments. ^**p < 0.01; ^***p < 0.001; ^****p < 0.0001; ns, not significant